Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RSV LID ΔM2-2 1030s vaccine in RSV-seronegative infants
NCT02952339Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Aug 2016
- Primary completion
- Jul 2017
- Modality
- Live Attenuated Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in respiratory syncytial virus infection (RSV) comparing RSV LID ΔM2-2 1030s vaccine with Placebo (2 arms). Primary endpoints: Grades of study product-related solicited adverse events at 28 days, Grades of study product-related unsolicited adverse events at 28 days and 7 more. Started Aug 2016; status: completed.
02
Drugs
RSV LID ΔM2-2 1030s
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT02952339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02952339.